Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00092235 · ClinicalTrials.gov registry record
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
A clinical trial of Chronic Graft vs. Host Disease, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 650
- Enrollment target
- 1
- Study location
NCT00092235 is a study of Chronic Graft vs. Host Disease that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 650 participants, above the 17-participant average among 3 other Chronic Graft vs. Host Disease trials with a reported enrollment target (3724% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00092235, a study of Chronic Graft vs. Host Disease, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 650 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: * Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT). It is characterized by immune dysregulation, immunodeficiency, impaired organ function, and decreased survival. * Each year about 8000 patients receive allogeneic hematopoietic stem cell transplant (alloHSCT) in North America and about 50% of patients who are transplanted develop cGVHD. * Chronic GVHD is also a disorder that simultaneously affects many organ systems in highly variable fashion and requires complex and coordinated medical management by multiple medical specialties. There is an urgent need for progress in understanding and effective treatments for cGVHD as it is one of the most serious complications of cancer therapy and hematopoietic stem cell transplantation. Objectives: * To establish a multidisciplinary clinic infrastructure for study of the pathogenesis and natural history of cGVHD. * To prospectively identify clinical and biological prognostic markers in patients with cGVHD * To develop clinically relevant cGVHD grading scales * To identify novel biological characteristics of cGVHD and to describe them in the context of clinical history and presentation * To identify potential clinical and biological markers of cGVHD activity * To improve understanding of the biology of cGVHD-associated graft-versus-tumor effects * To identify potential patients for cGVHD treatment protocols at the NCI and NIH Eligibility: -Patients age 1 and older referred by the primary transplant physician for the evaluation of chronic graft-versus-host disease independent of underlying diagnosis. Design: * Patient undergoes initial clinical and laboratory multispecialty work-up at the NCI cGVHD clinic. * Minimally invasive biopsies and rarely, deep tissue biopsy may be obtained to confirm the diagnosis and/or rule-out other pathologic process (in adults only). * Long tem data col
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2004-10-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00092235
The ClinicalTrials.gov registry entry for NCT00092235 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 650 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 17-participant average among 3 other Chronic Graft vs. Host Disease trials with a reported enrollment target (3724% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Graft vs. Host Disease appearing as the primary indexed condition, and to 0 interventions.
NCT00092235 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00092235 about?
NCT00092235 is a clinical study titled "Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease". Background: * Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT). It is characterized by immune dysregulation, immunodeficiency, impaired organ function, and decreased surv...
What is the current status of trial NCT00092235?
This trial is currently recruiting. The enrollment target is 650 participants. The study started on 2004-10-26.
What conditions does trial NCT00092235 study?
This clinical trial studies the following conditions: Chronic Graft vs. Host Disease.
Who is sponsoring clinical trial NCT00092235?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00092235 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Graft vs. Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
COMPLETED · Phase 1
-
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.